TCA Dose Reduction for CYP2D6 Intermediate Metabolizers
For CYP2D6 intermediate metabolizers (IM) receiving tricyclic antidepressants, reduce the starting dose by 25% according to CPIC guidelines 1.
Pharmacogenetic Dosing Recommendations
The Clinical Pharmacogenetics Implementation Consortium (CPIC) provides standardized dosing adjustments for TCAs based on CYP2D6 metabolizer status:
CYP2D6 Intermediate Metabolizers (IM)
- Dose reduction: 25% of standard starting dose 1
- This applies to amitriptyline, clomipramine, doxepin, imipramine, and trimipramine
- Utilize therapeutic drug monitoring to guide subsequent dose adjustments 1
CYP2D6 Ultra-Rapid Metabolizers (UM)
- Avoid TCAs due to potential lack of efficacy 1
- If TCA use is warranted, consider titrating to higher target doses (125-200% depending on specific TCA) 1
- Alternative: select drugs not metabolized by CYP2D6
CYP2D6 Poor Metabolizers (PM)
- Avoid TCAs entirely 1
- Consider alternative antidepressants not primarily metabolized by CYP2D6 (e.g., desipramine) 1
Important Clinical Considerations
Common pitfall: The Dutch Pharmacogenetics Working Group (DPWG) provides more specific, PK-based dosing for ultra-rapid metabolizers with different percentages for each TCA (amitriptyline 125%, clomipramine 150%, doxepin 200%, imipramine 170%, nortriptyline 160%), while CPIC recommends avoiding TCAs in this population 1. The CPIC recommendation to avoid is more conservative and prioritizes safety.
CYP2C19 considerations: For imipramine specifically, CYP2C19 poor metabolizers should receive a 30% dose reduction, while intermediate metabolizers should consider alternative drugs 2. Amitriptyline also has CYP2C19 interactions requiring dose adjustments 1.
Always implement therapeutic drug monitoring regardless of genotype-guided dosing, as individual patient factors beyond pharmacogenetics influence TCA metabolism and response 1.